India, Feb. 24 -- Bayer has announced that its cancer drug, Nubeqa(R) has lately received approval in India for an expanded indication, offering clinicians access to a non-chemotherapy treatment option for patients who may not be able to tolerate chemotherapy.

The expanded approval in India allows for Nubeqa to be used in combination with androgen-deprivation therapy (ADT) for the treatment of adult patients with metastatic hormone-sensitive prostate cancer (mHSPC). Nubeqa was launched in India in June 2022 with its first approved indication for non-metastatic castration-resistant prostate cancer (nmCRPC), followed in 2023 by approval for its use together with docetaxel and ADT in metastatic disease.

In India, prostate cancer is most co...